Bibliography
- Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol 2002;16:19-33
- Gaitanis G, Velegraki A, Mayser P, et al. Skin diseases associated with Malassezia yeasts: facts and controversies. Clin Dermatol 2013;31:455-63
- Gupta AK, Kogan N, Batra R. Pityriasis versicolor: a review of pharmacological treatment options. Expert Opin Pharmacother 2005;6:165-78
- Mendez-Tovar LJ. Pathogenesis of dermatophytosis and tinea versicolor. Clin Dermatol 2010;28:185-9
- Borelli D, Jacobs PH, Nall L. Tinea versicolor: epidemiologic, clinical, and therapeutic aspects. J Am Acad Dermatol 1991;25(2 Pt 1):300-5
- Faergemann J. Pityrosporum species as a cause of allergy and infection. Allergy 1999;54:413-19
- Rotta I, Sanchez A, Gonçalves P, et al. Efficacy and safety of topical antifungals in the treatment of dermatomycosis: a systematic review. Br J Dermatol 2012;166:927-33
- Di Fonzo EM, Martini P, Mazzatenta C, et al. Comparative efficacy and tolerability of Ketomousse (ketoconazole foam 1%) and ketoconazole cream 2% in the treatment of pityriasis versicolor: results of a prospective, multicentre, randomised study. Mycoses 2008;51:532-5
- Shi TW, Zhang JA, Tang YB, et al. A randomized controlled trial of combination treatment with ketoconazole 2% cream and adapalene 0.1% gel in pityriasis versicolor. J Dermatolog Treat 2014. [ Epub ahead of print]
- Brogden RN, Goa KE. Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Drugs 1997;53:511-19
- Vermeer BJ, Staats CC. The efficacy of a topical application of terbinafine 1% solution in subjects with pityriasis versicolor: a placebo-controlled study. Dermatology 1997;194(Suppl 1):22-4
- Janssen Pharmaceuticals. Nizoral® (Ketoconazole) Tablets. Drugs@FDA: FDA Approved Drug Products. 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/018533s041lbl.pdf
- Ketoconazole - Risk of Potentially Fatal Liver Toxicity - For Health Professionals. 2013. Available from: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/34173a-eng.php
- PrApo-Ketoconazole. Ketoconazole tablets USP 200 mg. Government of Canada HC. Drug product database online query. 2012. Available from: http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=60554&lang=eng
- European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. European Medicines Agency. 2013. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001855.jsp&mid=WC0b01ac058004d5c1
- Faergemann J, Djärv L. Tinea versicolor: treatment and prophylaxis with ketoconazole. Cutis 1982;30:542-5, 550
- Rausch LJ, Jacobs PH. Tinea versicolor: treatment and prophylaxis with monthly administration of ketoconazole. Cutis 1984;34:470-1
- Kose O, Bülent Taştan H, Riza Gür A, et al. Comparison of a single 400 mg dose versus a 7-day 200 mg daily dose of itraconazole in the treatment of tinea versicolor. J Dermatolog Treat 2002;13:77-9
- Sporanox® (itraconazole) Capsules. Drugs@FDA: FDA Approved Drug Products. 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020083s053lbl.pdf
- Cauwenbergh G, De Doncker P, Stoops K, et al. Itraconazole in the treatment of human mycoses: review of three years of clinical experience. Clin Infect Dis 1987;9(Suppl 1):S146-52
- Galimberti RL, Villalba I, Galarza S, et al. Itraconazole in pityriasis versicolor: ultrastructural changes in malassezia furfur produced during treatment. Rev Infect Dis 1987;9:S134-8
- Mohanty J, Sethi J, Sharma MK. Efficacy of itraconazole in the treatment of tinea versicolor. Indian J Dermatol Venereol Leprol 2001;67:240-1
- Wahab MA, Ali ME, Rahman MH, et al. Single dose (400 mg) versus 7 day (200 mg) daily dose itraconazole in the treatment of tinea versicolor: a randomized clinical trial. Mymensingh Med J 2010;19:72-6
- Kokturk A, Kaya TI, Ikizoglu G, et al. Efficacy of three short-term regimens of itraconazole in the treatment of pityriasis versicolor. J Dermatolog Treat 2002;13:185-7
- Faergemann J, Gupta AK, Al Mofadi A, et al. Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor. Arch Dermatol 2002;138:69-73
- Diflucan® (Fluconazole Tablets) (Fluconazole Injection – for intravenous infusion only) (Fluconazole for Oral Suspension). Drugs@FDA: FDA Approved Drug Products. 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019949s058,019950s062,020090s042lbl.pdf
- Bhogal CS, Singal A, Baruah MC. Comparative efficacy of ketoconazole and fluconazole in the treatment of pityriasis versicolor: a one year follow-up study. J Dermatol 2001;28:535-9
- Partap R, Kaur I, Chakrabarti A, et al. Single-dose fluconazole versus itraconazole in pityriasis versicolor. Dermatology 2004;208:55-9
- Yazdanpanah MJ, Azizi H, Suizi B. Comparison between fluconazole and ketoconazole effectivity in the treatment of pityriasis versicolor. Mycoses 2007;50:311-13
- Karakaş M, Durdu M, Memişoğlu HR. Oral fluconazole in the treatment of tinea versicolor. J Dermatol 2005;32:19-21
- Dehghan M, Akbari N, Alborzi N, et al. Single-dose oral fluconazole versus topical clotrimazole in patients with pityriasis versicolor: a double-blind randomized controlled trial. J Dermatol 2010;37:699-702
- Odds F, Ausma J, Gerven FV, et al. In vitro and in vivo activities of the Novel azole antifungal agent R126638. Antimicrob Agents Chemother 2004;48:388-91
- Faergemann J, Ausma J, Vandeplassche L, et al. The efficacy of oral treatment with pramiconazole in pityriasis versicolor: a phase II a trial. Br J Dermatol 2007;156:1385-8
- Faergemann J, Todd G, Pather S, et al. A double-blind, randomized, placebo-controlled, dose-finding study of oral pramiconazole in the treatment of pityriasis versicolor. J Am Acad Dermatol 2009;61:971-6
- Hu SW, Bigby M. Pityriasis versicolor: a systematic review of interventions. Arch Dermatol 2010;146:1132
- Gupta AK, Lane D, Paquet M. Systematic review of systemic treatments for tinea versicolor and evidence-based dosing regimen recommendations. J Cutan Med Surg 2014;18:79-90
- Budimulja U, Paul C. One-week terbinafine 1% solution in pityriasis versicolor: twice-daily application is more effective than once-daily. J Dermatolog Treat 2002;13:39-40
- Gupta AK, Kohli Y, Li A, et al. In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole and terbinafine. Br J Dermatol 2000;142:758-65
- Miranda KC, de Araujo CR, Costa CR, et al. Antifungal activities of azole agents against the Malassezia species. Int J Antimicrob Agents 2007;29:281-4